4//SEC Filing
Sofinnova Venture Partners IX, L.P. 4
Accession 0001104659-20-069570
CIK 0001659323other
Filed
Jun 2, 8:00 PM ET
Accepted
Jun 3, 8:20 PM ET
Size
13.4 KB
Accession
0001104659-20-069570
Insider Transaction Report
Form 4
Sofinnova Management IX, L.L.C.
10% Owner
Transactions
- Sale
Ordinary Shares
2020-06-01$1.69/sh−100,000$169,120→ 1,626,514 total - Sale
Ordinary Shares
2020-06-02$1.61/sh−400,000$642,960→ 1,226,514 total
HEALY JAMES
Director10% Owner
Transactions
- Sale
Ordinary Shares
2020-06-01$1.69/sh−100,000$169,120→ 1,626,514 total - Sale
Ordinary Shares
2020-06-02$1.61/sh−400,000$642,960→ 1,226,514 total
POWELL MICHAEL
10% Owner
Transactions
- Sale
Ordinary Shares
2020-06-02$1.61/sh−400,000$642,960→ 1,226,514 total - Sale
Ordinary Shares
2020-06-01$1.69/sh−100,000$169,120→ 1,626,514 total
Sofinnova Venture Partners IX, L.P.
10% Owner
Transactions
- Sale
Ordinary Shares
2020-06-02$1.61/sh−400,000$642,960→ 1,226,514 total - Sale
Ordinary Shares
2020-06-01$1.69/sh−100,000$169,120→ 1,626,514 total
Footnotes (4)
- [F1]The price realized by the reporting person from the sales reported in Table I of this Form 4 is less than the market price of the Issuer's Ordinary Shares on the date of any purchase transaction that is potentially matchable during the previous six months. Thus, no short-swing profit is recoverable for purposes of Section 16(b).
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The securities are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.58 to $1.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
Documents
Issuer
Iterum Therapeutics plc
CIK 0001659323
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001612133
Filing Metadata
- Form type
- 4
- Filed
- Jun 2, 8:00 PM ET
- Accepted
- Jun 3, 8:20 PM ET
- Size
- 13.4 KB